GlassScriptPhysician profile
Shareen M Greenbaum
NPI 1912039363
$14,705.87
in general payments reported to CMS, 2019-2025
39 companies · $8,349 in 2025
The $8,349 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $521 · 2021: $878 · 2022: $2,180 · 2023: $1,096 · 2024: $1,080 · 2025: $8,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,524.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $7,258.06 | 2025 | M22 |
| Biotissue Holdings INC. | $1,590.17 | 2019-2025 | |
| Alcon Vision LLC | $751.26 | 2019-2025 | Lensx, Hydrus Microstent, Tryptyr |
| New World Medical,INC. | $599.19 | 2022-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Johnson & Johnson Surgical Vision, INC. | $544.08 | 2020-2025 | Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $468.92 | 2020-2025 | Cequa |
| Allergan, INC. | $393.89 | 2019-2022 | |
| Abbvie INC. | $276.34 | 2023-2025 | |
| Dompe US, INC. | $274.72 | 2023-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $274.25 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Horizon Therapeutics Plc | $263.44 | 2021-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $241.20 | 2019-2023 | |
| Ocular Therapeutix, INC. | $206.81 | 2021-2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $158.74 | 2019-2021 | |
| Sight Sciences, INC. | $145.47 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $122.18 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $111.23 | 2019-2022 | |
| Beaver-Visitec International, INC. | $94.31 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.77 | 2019-2020 | |
| Merz North America, INC. | $87.10 | 2019 | |
| Shire North American Group INC | $78.12 | 2019 | |
| Kala Pharmaceuticals, INC. | $67.86 | 2020-2021 | |
| Rxsight INC | $67.66 | 2021-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Thea Pharma INC. | $62.60 | 2023-2025 | Iyuzeh |
| Glaukos Corporation | $61.48 | 2019-2024 | Idose |
| Harrow Eye, LLC | $55.37 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $54.19 | 2024 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $53.19 | 2025 | Acthar |
| Oyster Point Pharma, INC. | $43.91 | 2022-2025 | Tyrvaya |
| Rayner Intraocular Lenses Limited | $37.10 | 2023 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Regeneron Healthcare Solutions, INC. | $25.49 | 2023 | Eylea |
| Akorn, INC. | $24.04 | 2020 | |
| Ivantis, INC | $20.75 | 2021 | |
| Alcon Research LLC | $20.60 | 2019 | |
| Akorn Operating Company LLC | $20.03 | 2021 | |
| Omeros Corporation | $19.65 | 2020 | |
| Astellas Pharma US INC | $15.61 | 2024 | Izervay |
| Kaleo, INC. | $14.10 | 2021 | |
| Heru, INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shareen Greenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.